Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$1.89
-2.8%
$1.80
$1.33
$3.58
$88.80M0.7463,572 shs16,381 shs
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
$3.26
-3.6%
$4.00
$2.25
$8.54
$304.91M2.121.23 million shs1.37 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.64
+2.7%
$6.50
$4.58
$9.78
$383.07M1.89512,764 shs190,914 shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$4.40
-3.1%
$4.65
$2.86
$16.62
$301.05M1.9824,135 shs210,218 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-2.84%-0.79%-8.94%+19.26%-35.00%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-3.58%+22.52%-29.00%+20.26%-48.02%
CryoPort, Inc. stock logo
CYRX
CryoPort
+2.69%+4.80%+30.82%+43.07%+22.04%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-3.08%-3.51%+8.64%+35.38%-58.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
2.053 of 5 stars
3.33.00.00.01.81.70.0
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
1.6669 of 5 stars
3.42.00.00.00.60.80.6
CryoPort, Inc. stock logo
CYRX
CryoPort
2.2011 of 5 stars
3.42.00.00.02.12.50.0
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
1.7752 of 5 stars
3.51.00.00.00.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
2.50
Moderate Buy$8.00324.40% Upside
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
2.86
Moderate Buy$17.00421.63% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0043.98% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
3.00
Buy$24.50456.82% Upside

Current Analyst Ratings Breakdown

Latest ADAG, CYRX, CMPS, and OLMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/23/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ In-Line$11.00 ➝ $6.00
5/27/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$12.00
5/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $18.00
5/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.00
5/13/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/12/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/28/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$100K888.02N/AN/A$1.14 per share1.65
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$2.26 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.68N/AN/A$7.44 per share1.03
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$7.14 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-$33.42MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$155.12M-$1.99N/AN/AN/AN/A-81.75%-59.42%7/30/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$129.47M-$2.01N/AN/AN/AN/A-42.31%-38.32%8/5/2025 (Estimated)

Latest ADAG, CYRX, CMPS, and OLMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.49-$0.36+$0.13-$0.36N/AN/A
5/8/2025Q1 2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$0.47-$0.44+$0.03-$0.24N/AN/A
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
N/AN/AN/AN/AN/A
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.01
2.30
2.30
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
0.11
10.18
10.18
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/A
15.22
15.22

Institutional Ownership

CompanyInstitutional Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
9.51%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
46.19%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%

Insider Ownership

CompanyInsider Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
21.20%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
3.93%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
16.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
26047.11 million37.12 millionNot Optionable
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
12093.56 million89.89 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
7068.42 million57.23 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adagene stock logo

Adagene NASDAQ:ADAG

$1.82 -0.12 (-6.19%)
As of 07/3/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

COMPASS Pathways stock logo

COMPASS Pathways NASDAQ:CMPS

$3.26 -0.12 (-3.58%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$3.26 +0.00 (+0.03%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.64 +0.20 (+2.69%)
Closing price 07/3/2025 01:29 PM Eastern
Extended Trading
$7.42 -0.22 (-2.81%)
As of 07/3/2025 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$4.40 -0.14 (-3.08%)
As of 07/3/2025 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.